Notably, in our preclinical studies, BCL-XL degradation in MOLT-4 T-ALL xenografts lasted much longer (approximately 2 weeks) than that in human peripheral WBCs after a single dosing, suggesting that the effect of DT2216 on tumor levels of BCL-XL might be underestimated based on its effect on WBC BCL-XL [5]. The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.